Company Overview and News

Would IAG’s Friendly Takeover Be Best For Norwegian?

2018-04-16 aviationweek
International Airlines Group (IAG) has built a reputation as one of the few large airline groups that knows how to make consolidation work. All its units—British Airways (BA), Iberia, Vueling, Level and Aer Lingus—are making healthy profits, at least partly due to IAG’s synergies and strict management control. The company, led by Willie Walsh, has also been successful since its creation in 2011 because it knew when to say no.

Flash - Lufthansa'a Alitalia bid the 'most promising': Minister - France 24

2018-04-16 france24
Lufthansa emerged as the number one candidate to take over Alitalia on Monday after an Italian government minister called the German airline's bid the "most promising".

Lufthansa's Alitalia bid the 'most promising': Minister

2018-04-16 channelnewsasia
MILAN: Lufthansa emerged as the number one candidate to take over Alitalia on Monday (Apr 16) after an Italian government minister called the German airline's bid the "most promising".

Lufthansa's offer for Alitalia is the 'most promising': minister

Alitalia has been the subject of three offers or expressions of interest, with Britain's budget airline EasyJet one of the other companies keen on Italy's struggling flagship airline.

Lufthansa’a Alitalia bid the ‘most promising’, says minister

2018-04-16 themalaymailonline
People walk in the Alitalia departure hall at Fiumicino international airport in Rome, Italy July 24, 2015. — Reuters picMILAN, April 16 — Alitalia moved a step closer to being sold to Lufthansa today after an Italian government minister called the German airline’s bid the “most promising”.

Embattled Italian airline Alitalia attracts buying interest from EasyJet, Lufthansa

2018-04-11 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:

Global Eagle Reports Financial Results for Fourth Quarter and Full Year 2017

2018-04-02 globenewswire
Global Eagle recently completed funding of Searchlight Capital Partners investment Service revenue growth across Connectivity segment Media & Content segment gross margins improve versus Third Quarter 2017

Flash - EasyJet chief says European airline shakeup is not over - France 24

2018-03-28 france24
The European aviation sector is likely to see further consolidation after a number of airline bankruptcies, the new chief executive of British low-cost airline EasyJet said on Wednesday.

UK’s easyJet confident of securing Middle East, Asian partners for long-haul connections growth

2018-03-27 themalaymailonline
A British Airways aircraft lands next to an EasyJet plane ready for takeoff at Cointrin airport in Geneva September 26, 2017. — Reuters picBERLIN, March 27 — UK’s easyJet said it hopes to add Middle East and Asian carriers to its long-haul connections programme, which enables travellers to buy multiple flights in a single transaction.

Airline Stock Roundup: A4A's Spring Travel Forecast Bullish, UAL & AAL in Focus

2018-03-21 zacks
In the last five trading days, Airlines for America (‘A4A’) — a premier trade organization — for U.S. carriers unveiled an upbeat forecast for the current spring season. Per the projection, these companies are expected to profit considerably this spring (Mar 1-Apr 30) as travel demand is anticipated to increase 4% year over year.

Ryanair to take control of Niki Lauda's airline - Channel NewsAsia

2018-03-20 channelnewsasia
LONDON: Irish low-cost carrier Ryanair announced on Tuesday (Mar 20) that it will take control of an Austrian airline from racing driving legend Niki Lauda for about €50 million (US$62 million).

Ryanair boss secures long coveted Airbus fleet with Niki Lauda deal

Ryanair’s chief executive Michael O’Leary has bagged himself the fleet of Airbus aircraft he has long coveted after agreeing to buy a stake in three-times Formula One world champion Niki Lauda’s airline.

Ryanair Buys Niki Lauda Airline in Rare Foray Into Dealmaking - Bloomberg

2018-03-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

UPDATE 2-Ryanair to buy Niki Lauda airline in challenge to Lufthansa

2018-03-20 reuters
BERLIN/DUESSELDORF, Germany (Reuters) - Ryanair (RYA.I) has agreed to buy a majority stake in the new Austrian leisure airline founded by former motor racing champion Niki Lauda in a major push on the German and Austrian markets dominated by Lufthansa (LHAG.DE).

Ryanair expands in Germany, Austria with Laudamotion deal

2018-03-20 themalaymailonline
Niki Lauda addresses the media aboard a Laudamotion plane in Duesseldorf, Germany, March 20, 2018. — Reuters picBERLIN, March 20 — Ryanair plans to buy a stake in new Austrian leisure carrier Laudamotion, helping former motor racing champion Niki Lauda to get the airline up and running and giving the Irish carrier a bigger presence in Germany and Austria.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...